4SC 301 / 4SC 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   19 News 
  • ||||||||||  4SC 301 / 4SC
    Journal:  Tanshinone IIa attenuates vascular calcification through inhibition of NF-κB and β-catenin signaling pathways (Pubmed Central) -  Jan 4, 2023   
    Similar to Tanshinone IIa, inhibition of NF-κB and β-catenin signaling using the chemical inhibitors SC75741 and LF3 attenuated high phosphate-induced vascular smooth muscle cell calcification. These results suggest that Tanshinone IIa attenuates vascular calcification at least in part through inhibition of NF-κB and β-catenin signaling, and Tanshinone IIa may be a potential drug for the treatment of vascular calcification.
  • ||||||||||  4SC 301 / 4SC
    Journal, Epigenetic controller:  The short-chain fatty acid butyrate accelerates vascular calcification via regulation of histone deacetylases and NF-κB signaling. (Pubmed Central) -  Oct 14, 2022   
    Intriguingly, the NF-κB inhibitor SC75741 significantly attenuated butyrate-induced calcification and the osteogenic gene Msx2 expression in VSMCs...This study reveals that butyrate accelerates vascular calcification via its dual effects on HDAC inhibition and NF-κB activation. Our data provide novel insights into the role of microbe-host interaction in vascular calcification, and may have implications for the development of potential therapy for vascular calcification.
  • ||||||||||  4SC 301 / 4SC
    Journal:  Melatonin Inhibits NF-κB/CREB/Runx2 Signaling and Alleviates Aortic Valve Calcification. (Pubmed Central) -  Jul 9, 2022   
    Besides, the NF-κB inhibitor (SC75741) reduced OST medium-induced VIC calcification to a similar extent to melatonin at 10 nmol/L...Activation of the melatonin/MT1-axis significantly reduced VIC calcification by targeting the NF-κB/CREB/Runx2 pathway. Targeting melatonin/MT1 signaling may be a potential therapeutic strategy for CAVD.
  • ||||||||||  4SC 301 / 4SC
    Journal:  Promising antivirals for PLpro of SARS-CoV-2 using virtual screening, molecular docking, dynamics, and MMPBSA. (Pubmed Central) -  May 6, 2022   
    Molecular docking results suggested that five molecules (44560613, 136277567, S5652, SC75741, and S3833) had good binding affinities at both sites of PLpro...Molecular Mechanics/Position-Boltzmann Surface Area (MMPBSA) analysis confirmed that antiviral molecules bound PLpro complex had lower energy (-184.72 ± 7.81 to -215.67 ± 6.73 kJ/mol) complexes. Noticeably, computational approaches revealed promising antivirals candidates for PLpro, which may be further tested by biochemical and cell-based assays to assess their potential for SARS-CoV-2.Communicated by Ramaswamy H. Sarma.
  • ||||||||||  4SC 301 / 4SC
    Journal:  S100A9 induces nucleus pulposus cell degeneration through activation of the NF-κB signaling pathway. (Pubmed Central) -  Oct 6, 2021   
    We concluded that S100A9 induced NP cell apoptosis, caused matrix degradation and amplified the inflammatory response through the activation of the NF-κB signalling pathway. Inhibition of these pro-apoptotic, pro-degradation and pro-inflammatory effects induced by S100A9 in NP may be a favourable therapeutic strategy to slow lumbar disc degeneration.
  • ||||||||||  4SC 301 / 4SC
    Journal:  The NF-κB inhibitor, SC75741, is a novel antiviral against emerging tick-borne bandaviruses. (Pubmed Central) -  Aug 8, 2021   
    We demonstrated that the NF-κB inhibitor, SC75741, reduces viral RNA synthesis of SFTSV and HRTV using our MG platform and validated these results using infectious SFTSV and HRTV. These results may lead to the use of MG systems as potential screening systems for the identification of antiviral compounds and yield novel insights into host-factors that could play role in bandavirus transcription and replication.